(2-甲基-1-丙基-1H-吲哚-3-基)-1-萘甲酮 | 155471-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (2-甲基-1-丙基-1H-吲哚-3-基)-1-萘甲酮
• 中文别名: (2-甲基-1-丙基-1H-吲哚-3-基)-1-萘基甲酮
• 英文名称: (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone
• 英文别名: JWH 015；(2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone
• CAS: 155471-08-2
• 化学式: C₂₃H₂₁NO
• 分子量: 327.426
• InChiKey: LJSBBBWQTLXQEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-methyl-N-phenyl-1H-indole-3-carboxamide 在 4-二甲氨基吡啶 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.33h， 生成 (2-甲基-1-丙基-1H-吲哚-3-基)-1-萘甲酮
  参考文献：
  名称：

  [3 + 2]-Annulations of N-Hydroxy Allenylamines with Nitrosoarenes: One-Pot Synthesis of Substituted Indole Products

  摘要：

  In the presence of O-2 and an IPrCuCl additive (5 mol %), [3 + 2]-annulation reactions of N-hydroxyaniline with nitrosobenzenes in cold toluene form isoxazolidin-5-ol derivatives. Heating the same reaction mixture with DBU in toluene affords highly functionalized indole products efficiently. This method provides short synthesis of several bioactive molecules including WIN 48098, WIN 53365, and JWH 015.

  DOI：

  10.1021/acs.orglett.5b03447

文献信息

• PAINKILLING ASSOCIATION COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE
  申请人：Auguet Michel

  公开号：US20090270400A1

  公开（公告）日：2009-10-29

  The invention relates to a product comprising (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydrolmidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected from morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or out over the time for pain treatment or prevention.

  该发明涉及一种产品，其中包含(1R)-1-[((2R)-2-氨基-3-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}二硫)甲基]-2-[(8S)-8-(环己甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-2-氧代乙胺，与吗啡、类似物或吗啡衍生物、钠通道抑制剂、非甾体抗炎药（AINS）、谷氨酸系统抑制剂、三环抗抑郁药和GABA能衍生物中选择的镇痛药联合使用，用于同时治疗或预防疼痛的分隔或延时。
• CB2-selective cannabinoid analogues
  申请人：Martin R. Billy

  公开号：US20050009903A1

  公开（公告）日：2005-01-13

  Cannabinoid analogues that exhibit specificity for the CB 2 cannabinoid receptor are provided. The analogues are 1-methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Δ 8 -tetrahydrocannabinols and 1-alkyl-3(1-naphthoyl)indoles. The compounds are useful for the treatment of pain (especially pain resulting from inflammation) and cancer (especially glioma tumors).

  提供了对CB2大麻素受体具有特异性的大麻素类似物。这些类似物是1-甲氧基-、1-去氧-11-羟基-和11-羟基-1-甲氧基-Δ8-四氢大麻酚以及1-烷基-3(1-萘酰)吲哚。这些化合物对于治疗疼痛（尤其是由炎症引起的疼痛）和癌症（尤其是胶质瘤）具有用途。
• PHARMACEUTICAL COMPOSITIONS
  申请人：LAZZARI Paolo

  公开号：US20100216785A1

  公开（公告）日：2010-08-26

  Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, O) from 0.01 to 95% of one or more oils selected from esters of C 4 -C 32 acids or C 4 -C 32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A′: AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.

  药物组成的微乳液包含以下组分（按重量百分比计算），各组分总和为100％：S）从0.01到95％的一种或多种化合物，选自表面活性剂、聚合物，形成有序结构，如：聚集体、胶束、液晶、囊泡，在它们被溶解的液体中，O）从0.01到95％的一种或多种油，选自C4-C32酸酯或C4-C32酸，PA）从0.001到90％的化合物，具有亲和力为公式A'的CB1和/或CB2大麻素受体，AD）从0到60％的一种或多种化合物，按重量计算，选自调节剂，水和/或油极性的调节剂，组分S）的膜曲率调节剂，共表面活性剂，水或盐水溶液之差为100％，其中按重量比S）/PA）低于不含组分O）的微乳液的比例。
• Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors
  申请人：Neuroscienze Pharmaness S.C. A R.L.

  公开号：EP2223913A1

  公开（公告）日：2010-09-01

  Microemulsions of pharmaceutical compositions comprising the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solublized, O) from 0.01 to 95% of one or more oils selected from esters of C4-C32 acids or C4-C32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A': AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.

  医药组合物的微乳液包含以下组分（按重量百分比计），各组分之和为100%：S）从0.01到95%的一种或多种从表面活性剂、形成有序结构的聚合物，如：聚集体、胶束、液晶、囊泡，在它们溶解的液体中选择的化合物，O）从0.01到95%的一种或多种选择自C4-C32酸酯或C4-C32酸的油，PA）从0.001到90%的具有亲和力的化合物CB1和/或CB2大麻素受体的配方A'，AD）从0到60%的一种或多种选择自水和/或油极性修饰剂，成分S）的膜曲率修饰剂，共表面活性剂，水或盐水溶液的差异为100%，其中按重量比S）/PA）低于不含成分O）的微乳液。
• Detection of synthetic cannabinoids
  申请人：Randox Laboratories Ltd.

  公开号：EP2698385A1

  公开（公告）日：2014-02-19

  The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from immunogens enable said methods and kits.

  这项发明描述了检测和确定JWH和CP家族当前和未来合成大麻素的方法和试剂盒。从免疫原获得的独特抗体使这些方法和试剂盒成为可能。